🇺🇸 FDA
Patent

US 8598164

Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels

granted A61PA61P1/00A61P1/18

Quick answer

US patent 8598164 (Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels) held by Vertex Pharmaceuticals Incorporated expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
68
CPC classes
A61P, A61P1/00, A61P1/18, A61P13/00, A61P13/08